N1-((S)-1-((S)-1-(2-chlorobenzylamino)-1-oxo-4-phenylbutan-2-ylamino)-4-(neopentylamino)-1,4-dioxobutan-2-yl)-N4-(thiazol-2-yl)piperidine-1,4-dicarboxamide

ID: ALA4102324

Chembl Id: CHEMBL4102324

PubChem CID: 137659182

Max Phase: Preclinical

Molecular Formula: C36H46ClN7O5S

Molecular Weight: 724.33

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CC(C)(C)CNC(=O)C[C@H](NC(=O)N1CCC(C(=O)Nc2nccs2)CC1)C(=O)N[C@@H](CCc1ccccc1)C(=O)NCc1ccccc1Cl

Standard InChI:  InChI=1S/C36H46ClN7O5S/c1-36(2,3)23-40-30(45)21-29(42-35(49)44-18-15-25(16-19-44)31(46)43-34-38-17-20-50-34)33(48)41-28(14-13-24-9-5-4-6-10-24)32(47)39-22-26-11-7-8-12-27(26)37/h4-12,17,20,25,28-29H,13-16,18-19,21-23H2,1-3H3,(H,39,47)(H,40,45)(H,41,48)(H,42,49)(H,38,43,46)/t28-,29-/m0/s1

Standard InChI Key:  MFJLZSWPUNUKNF-VMPREFPWSA-N

Alternative Forms

1. Parent:

   

   ALA4102324

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 724.33

Molecular Weight (Monoisotopic): 723.2970

AlogP: 4.51

#Rotatable Bonds: 14

Polar Surface Area: 161.63

Molecular Species: NEUTRAL

HBA: 7

HBD: 5

#RO5 Violations: 1

HBA (Lipinski): 12

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 7.94

CX Basic pKa: ┄

CX LogP: 3.91

CX LogD: 3.81

Aromatic Rings: 3

Heavy Atoms: 50

QED Weighted: 0.16

Np Likeness Score: -1.45

References

1. Zhuang R, Gao L, Lv X, Xi J, Sheng L, Zhao Y, He R, Hu X, Shao Y, Pan X, Liu S, Huang W, Zhou Y, Li J, Zhang J..  (2017)  Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.,  126  [PMID:28027531] [10.1016/j.ejmech.2016.12.034]

2. Cao Y, Tu Y, Fu L, Yu Q, Gao L, Zhang M, Zeng L, Zhang C, Shao J, Zhu H, Zhou Y, Li J, Zhang J..  (2022)  Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment.,  233  [PMID:35218994] [10.1016/j.ejmech.2022.114211]

Source

Source(1):

• Scientific Literature